July 23 (Reuters) – Shares of Dr Reddy’s Laboratories declined 4.4% on Thursday after brokerages cut their earnings forecasts for the Indian drugmaker after weaker-than-expected quarterly results and semaglutide supply disruptions.
The stock was trading at 1,130 rupees, its lowest in over one year, and was the top loser on the pharma index and the Nifty 50.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
Brought to you by www.srnnews.com